HCW Biologics remains in a high-risk, pre-commercial development phase characterized by extreme revenue volatility and a persistent reliance on external financing. While the company reported a 1,290.8% revenue surge in 2026Q1, this appears to be driven by non-...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 14, 2026 | -$11.58-484.8% vs -$1.98 | $135,568+0.0% vs $135,568 |
Q2 2026 May 14, 2026 | $2.22+184.1% vs -$2.64 | $7M-0.2% vs $7M |
Q2 2026 Mar 31, 2026 | -$15.78-213.1% vs -$5.04 | $27,010-99.6% vs $7M |
Q4 2025 Nov 14, 2025 | -$12.12-227.8% vs $9.48 | $85,285-98.8% vs $7M |
Agreement includes pre-payment commitments for product sales and distribution of the second-generation multi-cytokine-based HCW11-006 for use as a reagent
HCW9302 is a best-in-class IL-2-based immunotherapeutic for treatment of autoimmune diseases through expanding and activating regulatory T cells Patent allowance received for use of HCW9302 as treatment for alopecia areata Phase 1 dose-escalating clinical study evaluating HCW9302 as monotherapy in patients with alopecia areata on track for completion in Q4 2026, continues to be well tolerated with no dose-limiting toxicities Preliminary readout of first two dose cohorts is encouraging -- patients diagnosed with alopecia areata show positive response after single dose of monotherapy at 3 micrograms/kg dose level MIRAMAR, Fla., Sept. 02, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat autoimmune diseases, cancer, and senescence-associated dysplasia, announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office (“USPTO”) for claims directed to use of HCW9302 to treat alopecia areata (U.S. Patent Application Publication No.
Human studies show that the TGF-β trap and IL-15 fusion used alone promotes expansion of progenitor CD8 + T cells and NK cells Company has incorporated the TGF-β/IL-15 moiety into the constructs of its second-generation fusion immunotherapeutics constructed with novel TRBC drug development platform MIRAMAR, Fla., Aug. 25, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat autoimmune diseases, cancer, and senescence-associated dysplasia, together with collaborators at leading research institutions, have identified a TGF-β trap and IL-15 fusion as a novel moiety with potential applications against diseased cells and viral infections.
MIRAMAR, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, today reported financial results and recent business highlights for the three and six months ended June 30, 2026.
Benchmark HCWB against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for HCW Biologics Inc. (HCWB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.66 | $577.08K | -0.03 | -97.89% | -14677.14% | -287.9% | — | |
| $34.54 | $7.13B | -12.47 | — | -7585.86% | -69.59% | — | |
| $26.38 | $3.3B | -202.92 | 91.34% | 6.15% | 15.05% | — | |
| $115.47 | $9.5B | -31.29 | -16.72% | -285.41% | -21.5% | — | |
| $26.39 | $3.32B | -8.02 | -4.26% | -386.32% | -87.98% | — | |
| $56.00 | $8.57B | 20.22 | 87.32% | 55.22% | 72.3% | — |
HCW Biologics Inc. (HCWB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
HCW Biologics Inc. (HCWB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 14, 2026·SEC
Aug 14, 2026·SEC
Jul 29, 2026·SEC
Mar 31, 2026·SEC
Get notified when HCWB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
HCW Biologics Inc. (HCWB) stock FAQ — growth, dividends, profitability & financials explained
HCW Biologics Inc. (HCWB) reported $6.7M in revenue for fiscal year 2025.
HCW Biologics Inc. (HCWB) saw revenue decline by 97.9% over the past year.
HCW Biologics Inc. (HCWB) reported a net loss of $4.9M for fiscal year 2025.
HCW Biologics Inc. (HCWB) has a return on equity (ROE) of -287.9%. Negative ROE indicates the company is unprofitable.
HCW Biologics Inc. (HCWB) had negative free cash flow of $12.1M in fiscal year 2025, likely due to heavy capital investments.
